1
|
Wen F, Jiang S, Yuan P, Liu J, Bai X, Zhao H, Chen X, Gong YB, Asmar R, Wang H. Vascular Health Promotion Project and Vascular Medicine in China-CCVM2004-2023. Vasc Health Risk Manag 2023; 19:741-751. [PMID: 38025518 PMCID: PMC10656854 DOI: 10.2147/vhrm.s432656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 10/25/2023] [Indexed: 12/01/2023] Open
Abstract
Cardiovascular disease(CVD) has become a major disease burden affecting people's health in China. Blood vessels are very important for human health and are the "sentinel" for the development of many cardiovascular and cerebrovascular diseases. The key to effectively preventing fatal, disabling heart, brain and peripheral vascular events lies in controlling traditional and non-traditional risk factors for vascular health from the source, and early assessment and intervention of early vascular lesions. Since 2004, China government promoted the early detection technology of vascular lesions and vascular medicine, and proposed the Beijing Vascular Health Stratification (BVHS) to provide suggestions for the examination, evaluation and management of risk factors, and to provide new ideas for lifelong maintenance of vascular health. This review mainly introduces the establishment and development of the clinical discipline of "vascular medicine" in the past 20 years in China, introduces the indicators for detecting vascular function and structure and the predictive value of vascular events, and carries out intelligent and digital management of vascular health throughout the life cycle of individualized prevention, treatment and rehabilitation for people with different parts or degrees of lesions, effectively reducing the occurrence and development of cardiovascular and cerebrovascular diseases, and the prospect of new technology in maintaining vascular health.
Collapse
Affiliation(s)
- Fang Wen
- Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, People’s Republic of China
| | - Shantong Jiang
- Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, People’s Republic of China
- Vascular Health Research Center of Peking University Health Science Center (VHRC-PKUHSC), Beijing, People’s Republic of China
- Beijing Shijingshan District Key Clinical Specialty of Vascular Medicine, Beijing, People’s Republic of China
- Heart and Vascular Health Research Center of Peking University Clinical Research Institute (HVHRC-PUCRI), Beijing, People’s Republic of China
| | - Ping Yuan
- Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, People’s Republic of China
- Vascular Health Research Center of Peking University Health Science Center (VHRC-PKUHSC), Beijing, People’s Republic of China
- Beijing Shijingshan District Key Clinical Specialty of Vascular Medicine, Beijing, People’s Republic of China
- Heart and Vascular Health Research Center of Peking University Clinical Research Institute (HVHRC-PUCRI), Beijing, People’s Republic of China
- Department of Scientific Research, Peking University Shougang Hospital, Beijing, People’s Republic of China
| | - Jinbo Liu
- Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, People’s Republic of China
- Vascular Health Research Center of Peking University Health Science Center (VHRC-PKUHSC), Beijing, People’s Republic of China
- Beijing Shijingshan District Key Clinical Specialty of Vascular Medicine, Beijing, People’s Republic of China
- Heart and Vascular Health Research Center of Peking University Clinical Research Institute (HVHRC-PUCRI), Beijing, People’s Republic of China
| | - Xiu Bai
- Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, People’s Republic of China
| | - Hongwei Zhao
- Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, People’s Republic of China
- Vascular Health Research Center of Peking University Health Science Center (VHRC-PKUHSC), Beijing, People’s Republic of China
- Beijing Shijingshan District Key Clinical Specialty of Vascular Medicine, Beijing, People’s Republic of China
- Heart and Vascular Health Research Center of Peking University Clinical Research Institute (HVHRC-PUCRI), Beijing, People’s Republic of China
- State Key Laboratory of Vascular Homeostasis and Remodeling, (Peking University), Beijing, People’s Republic of China
- Heart and Vascular Health Research Center of Chengdu Medical College (HVHRC-CMC), Chengdu, People’s Republic of China
| | - Xin Chen
- Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, People’s Republic of China
- Vascular Health Research Center of Peking University Health Science Center (VHRC-PKUHSC), Beijing, People’s Republic of China
- Beijing Shijingshan District Key Clinical Specialty of Vascular Medicine, Beijing, People’s Republic of China
- Heart and Vascular Health Research Center of Peking University Clinical Research Institute (HVHRC-PUCRI), Beijing, People’s Republic of China
- Heart and Vascular Health Research Center of Chengdu Medical College (HVHRC-CMC), Chengdu, People’s Republic of China
| | - Yan-Bing Gong
- Department of Scientific Research, Peking University Shougang Hospital, Beijing, People’s Republic of China
| | - Roland Asmar
- Foundation-Medical Research Institutes, Beirut, Lebanon
| | - Hongyu Wang
- Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, People’s Republic of China
- Vascular Health Research Center of Peking University Health Science Center (VHRC-PKUHSC), Beijing, People’s Republic of China
- Beijing Shijingshan District Key Clinical Specialty of Vascular Medicine, Beijing, People’s Republic of China
- Heart and Vascular Health Research Center of Peking University Clinical Research Institute (HVHRC-PUCRI), Beijing, People’s Republic of China
- State Key Laboratory of Vascular Homeostasis and Remodeling, (Peking University), Beijing, People’s Republic of China
- Heart and Vascular Health Research Center of Chengdu Medical College (HVHRC-CMC), Chengdu, People’s Republic of China
| |
Collapse
|
2
|
Cruz D, Oliveira-Pinto J, Mansilha A. The role of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers: a systematic review with meta-analysis of randomized controlled trials on limb amputation and ulcer healing. INT ANGIOL 2021; 41:63-73. [PMID: 34236155 DOI: 10.23736/s0392-9590.21.04722-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
INTRODUCTION Hyperbaric Oxygen Therapy (HBOT) is increasingly being used in the treatment of as diabetic foot ulcers (DFU). However, definitive evidence regarding its beneficial effects is still scarce. The present systematic review aims to analyse the role of HBOT in the prevention of limb amputation along with improvement of ulcer healing in patients with lower limbs DFU. EVIDENCE ACQUISITION Three databases were searched: PubMed, Scopus, and ISI Web of Knowledge. The search was enrolled during October 2020. Both titles and abstracts were examined by two independent reviewers. Only randomized controlled trials (RCTs) reporting a comparison between standard DFU treatment and standard treatment associated with HBOT were included. In all studies eligibility was assessed and data regarding studies characteristics, methods and considered outcomes was obtained. Odds ratio (OR) was used to evaluate amputation and complete ulcer healing rates. Percentage of ulcer reduction at two weeks was evaluated using the inverse variance method, and the values were compared using mean difference values. Meta-analysis was done using a fixed-effect model if I2 values were under 50%, and a random-effects model if not. EVIDENCE SYNTHESIS Eleven RCTs were included, with a total of 668 patients studied. Patients undergoing HBOT had lower risk of amputation (OR 0.53 95% CI 0.32-0.90, I2=31%). No difference was found in minor amputations (OR 0.89 95% CI 0.35-2.24, I2=69%). Regarding, healing rates, HBOT patients had greater chances of ulcer healing (OR 4,00 95% CI 1.54-10.44, I2=70%). It has also shown higher percentage of ulcer area reduction after two weeks of treatment in the HBOT group (mean difference 23.19%; 95% CI 14.86-31.52; I2=0%). CONCLUSIONS The present review offers evidence that adjuvant HBOT decreases risk of major amputation while promoting wound healing when combined to standard treatment in the management of DFU. These findings may have clinical relevance in a selected group of patients, yet further larger studies are still needed.
Collapse
Affiliation(s)
- Diogo Cruz
- Faculty of Medicine of Porto, Porto, Portugal -
| | - José Oliveira-Pinto
- Faculty of Medicine of Porto, Porto, Portugal.,Department of Vascular Surgery, Hospital São João, Porto, Portugal
| | - Armando Mansilha
- Faculty of Medicine of Porto, Porto, Portugal.,Department of Vascular Surgery, Hospital São João, Porto, Portugal
| |
Collapse
|